Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) were trading higher by 0.62 percent during Thursday's afternoon.
Halozyme Therapeutics disclosed earlier in the day that AbbVie Inc (NYSE: ABBV) has dosed its first subject in a clinical...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.